Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
| Autor: | Moehler, M., Maderer, A., Thuss-Patience, P.C., Brenner, B., Meiler, J., Ettrich, T.J., Hofheinz, R.-D., Al-Batran, S.E., Vogel, A., Mueller, L., Lutz, M.P., Lordick, F., Alsina, M., Borchert, K., Greil, R., Eisterer, W., Schad, A., Slotta-Huspenina, J., Van Cutsem, E., Lorenzen, S. |
|---|---|
| Zdroj: | In Annals of Oncology February 2020 31(2):228-235 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|